Causeway Capital Management LLC Sells 248,476 Shares of Smith & Nephew SNATS, Inc. $SNN

Causeway Capital Management LLC lowered its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 30.3% in the 3rd quarter, Holdings Channel reports. The fund owned 572,532 shares of the medical equipment provider’s stock after selling 248,476 shares during the quarter. Causeway Capital Management LLC’s holdings in Smith & Nephew SNATS were worth $20,777,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. AlphaCore Capital LLC bought a new stake in shares of Smith & Nephew SNATS during the second quarter valued at approximately $44,000. Huntington National Bank raised its holdings in Smith & Nephew SNATS by 1,837.0% in the third quarter. Huntington National Bank now owns 1,414 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 1,341 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Smith & Nephew SNATS by 1,222.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 2,486 shares of the medical equipment provider’s stock valued at $88,000 after acquiring an additional 2,298 shares during the period. Root Financial Partners LLC bought a new stake in Smith & Nephew SNATS during the third quarter worth about $102,000. Finally, MAI Capital Management grew its holdings in Smith & Nephew SNATS by 24.0% in the second quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock worth $134,000 after purchasing an additional 846 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SNN shares. Canaccord Genuity Group raised their target price on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday, March 5th. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Kepler Capital Markets upgraded shares of Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Finally, Wall Street Zen raised shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $36.25.

Smith & Nephew SNATS Stock Performance

Shares of SNN opened at $34.03 on Tuesday. The business’s 50 day moving average is $34.45 and its 200 day moving average is $34.89. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25. Smith & Nephew SNATS, Inc. has a 12-month low of $23.91 and a 12-month high of $38.79.

Smith & Nephew SNATS Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be given a dividend of $0.482 per share. The ex-dividend date is Friday, March 27th. This represents a dividend yield of 281.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.